Celgene (CELG) stock jumped over 30% in the past few trading days — and with good reason. Investors are excited over what is …
Celgene Corporation (NASDAQ:CELG) announced that the FDA has placed a partial clinical hold on five trials and a full clinical hold on one …
Gilead Sciences, Inc. Cowen analyst Phil Nadeau is out with a research note on shares of Gilead Sciences, Inc.
Celgene Corporation (NASDAQ:CELG) announced results from the phase 2a SLE-001 trial evaluating CC-220, the Company’s investigational, oral immunomodulatory compound, at the Annual European …
Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma (NASDAQ:XLRN) announced that they have completed target enrollment in the MEDALIST and BELIEVE Phase 3 studies of …
Celgene Corporation (NASDAQ:CELG) shares are down nearly 2% this morning, after the drug giant reported mixed first-quarter results. While Celgene reported an in-line Revlimid number, Otezla missed …
Celgene Corporation (NASDAQ:CELG) announced that its phase III SUNBEAM trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 …
Oppenheimer analysts are chiming in with upbeat forecasts on two biotech players: Celgene Corporation (NASDAQ:CELG) and Synergy Pharmaceuticals Inc (NASDAQ:SGYP). One analyst is out …
Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG), announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
In a research report released Thursday, BTIG analyst Dane Leone reiterated a Buy rating on shares of Celgene Corporation (NASDAQ:CELG) with a price …
